[18F]FDG-PET, which provides biomarker metrics for tumor aggressiveness, was systematically used in the LuPSMA trial by Hofman et al. to identify patients with aggressive lesions exhibiting low PSMA expression and to exclude them from LuPSMA therapy [5]. Here, FOLH1 is linked to neoplasm.